Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6362
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials ; volume:23 ; number:1 ; day:16 ; month:4 ; year:2021 ; pages:1-11 ; date:12.2021
Arthritis Research & Therapy ; 23, Heft 1 (16.4.2021), 1-11, 12.2021
- Creator
-
Combe, Bernard
Allanore, Yannick
Alten, Rieke
Caporali, Roberto
Durez, Patrick
Iannone, Florenzo
Nurmohamed, Michael T.
Toumi, Mondher
Lee, Sang Joon
Kwon, Taek Sang
Noh, Jiwon
Park, Gahee
Yoo, Dae Hyun
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13075-021-02487-x
- URN
-
urn:nbn:de:101:1-2021060506454477589204
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Combe, Bernard
- Allanore, Yannick
- Alten, Rieke
- Caporali, Roberto
- Durez, Patrick
- Iannone, Florenzo
- Nurmohamed, Michael T.
- Toumi, Mondher
- Lee, Sang Joon
- Kwon, Taek Sang
- Noh, Jiwon
- Park, Gahee
- Yoo, Dae Hyun
- SpringerLink (Online service)
Other Objects (12)
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis
Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis
Subcutaneous infliximab in Crohn’s disease patients with previous immunogenic failure of intravenous infliximab
The Effectiveness of Intravenous Golimumab Administered Directly After Infliximab in Rheumatoid Arthritis Patients
Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration
Improvement in disease activity among patients with rheumatoid arthritis who switched from intravenous infliximab to intravenous golimumab in the ACR RISE registry
Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis
Efficacy of Switching from Infliximab to Subcutaneous Golimumab in Patients with Rheumatoid Arthritis to Control Disease Activity or Adverse Events
Tocilizumab Effectiveness After Switching from Intravenous to Subcutaneous Route in Patients with Rheumatoid Arthritis: The RoSwitch Study
Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE Study
Response to Treatment with Intravenous Golimumab or Infliximab in Rheumatoid Arthritis Patients: PROMIS Results from the Real-World Observational Phase 4 AWARE Study
Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis